Comparative long‐term efficacy and safety of two paclitaxel‐coated balloons with different coating strategies for the treatment of drug‐eluting coronary stent restenosis
Open Access
- 18 September 2024
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (5) , 909-917
Abstract
Background: We previously showed non‐inferiority of a low‐dose paclitaxel‐coated balloon (PCB) with citrate excipient (Agent PCB) as compared to normal‐dose iopromide excipient (SeQuent Please PCB) in terms of angiographic and clinical endpoints at 12 months. The long‐term clinical efficacy and safety of Agent PCB is not defined.Methods: 262 patients (323 DES‐ISR lesions) were enrolled in this study and treated with either Agent PCB (125 patients, 151 lesions) in the ISAR‐DESIRE 3a trial or with SeQuent Please PCB (137 patients, 172 lesions) in the setting of the randomized ISAR‐DESIRE 3 trial with similar in‐ and exclusion criteria serving as historical control arm. The follow‐up period was extended to 7 years. The efficacy and safety endpoints of this analysis were target‐lesion revascularization (TLR), death, myocardial infarction (MI) and target lesion thrombosis (TLT) at 7 years.Results: At 7 years, 206 patients (78.6%) were alive. The risks of TLR (hazard ratio [HR]: 1.29, 95% confidence interval [CI]: 0.87–1.90; p = 0.205), death (HR: 1.38, 95% CI: 0.82‐2.35; p = 0.227), MI (HR: 1.10, 95% CI: 0.39–3.15; p = 0.852) and TLT (HR: 2.18, 95% CI: 0.20–24.10; p = 0.523) were comparable between Agent PCB and SeQuent PCB. Multivariate analysis showed comparable risks of TLR, death and MI between both PCB devices.Conclusions: In patients treated for DES‐ISR by angioplasty with Agent PCB and SeQuent Please PCB, there was no statistically significant difference in TLR at 7 years. Randomized trials with standardized lesion preparation and long‐term follow‐up are warranted to further evaluate comparative efficacy of both devices. (ClinicalTrials. gov Identifier: NCT02367495).Keywords
This publication has 25 references indexed in Scilit:
- Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent RestenosisJAMA, 2024
- A prospective trial of a novel low‐dose paclitaxel‐coated balloon therapy in patients with restenosis in drug‐eluting coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In‐stent REstenosis 3A (ISAR‐DESIRE 3A)Catheterization and Cardiovascular Interventions, 2021
- Recurrent Drug-Eluting Stent In-Stent Restenosis: A State-of-the-Art Review of Pathophysiology, Diagnosis, and ManagementCardiovascular Revascularization Medicine, 2020
- Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent RestenosisJACC, 2020
- Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosisInternational Journal of Cardiology, 2018
- Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary StentsJACC: Cardiovascular Interventions, 2017
- Five-Year Outcomes After Paclitaxel-Coated Balloon Angioplasty for Drug-Eluting Stent RestenosisThe American Journal of Cardiology, 2017
- Comparison of two different drug-coated balloons for the treatment of in-stent restenosis: A long-term single-centre experienceCardiovascular Revascularization Medicine, 2016
- Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials)The American Journal of Cardiology, 2016
- Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon CatheterJACC: Cardiovascular Interventions, 2012